...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Human vaccines & immunotherapeutics. >Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
【24h】

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants

机译：用13价肺炎球菌缀合物疫苗（PCV13）在巴西婴儿中替代10价肺炎球菌缀合物疫苗（PCV10）的成本效果分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Brazil currently has a 10-valent pneumococcal conjugate vaccine (PCV10) pediatric national immunization program (NIP). However, in recent years, there has been significant progressive increases in pneumococcal disease attributed to serotypes 3, 6A, and 19A, which are covered by the 13-valent PCV (PCV13). We sought to evaluate the cost-effectiveness and budget impact of switching from PCV10 to PCV13 for Brazilian infants from a payer perspective. A decision-analytic model was adapted to evaluate the clinical and economic outcomes of continuing PCV10 or switching to PCV13. The analysis estimated future costs ($BRL), quality-adjusted life-years (QALYs), and health outcomes for PCV10 and PCV13 over 5 y. Input parameters were from published sources. Future serotype dynamics were predicted using Brazilian and global historical trends. Over 5 y, PCV13 could prevent 12,342 bacteremia, 15,330 meningitis, 170,191 hospitalized pneumonia, and 25,872 otitis media cases, avert 13,709 pneumococcal disease deaths, gain 20,317 QALYs, and save 172 million direct costs compared with PCV10. The use of PCV13 in the Brazilian NIP could reduce pneumococcal disease, improve population health, and save substantial health-care costs. Results are reliable even when considering uncertainty for possible serotype dynamics with different underlying assumptions.
机译：巴西目前有一种10价肺炎球菌结合疫苗（PCV10）儿童国家免疫计划（NIP）。然而，近年来，13价PCV（PCV13）涵盖的血清型3、6A和19A导致的肺炎球菌疾病显著增加。我们试图从付款人的角度评估巴西婴儿从PCV10转为PCV13的成本效益和预算影响。采用决策分析模型来评估继续使用PCV10或改用PCV13的临床和经济结果。该分析估计了PCV10和PCV13在5年内的未来成本（BRL）、质量调整寿命年（QALY）和健康结果。输入参数来自已公布的来源。使用巴西和全球历史趋势预测未来血清型动态。5年以上，与PCV10相比，PCV13可预防12342例菌血症、15330例脑膜炎、170191例住院肺炎和25872例中耳炎，避免13709例肺炎球菌病死亡，获得20317例QALY，并节省1.72亿直接成本。在巴西NIP中使用PCV13可以减少肺炎球菌疾病，改善人群健康，并节省大量医疗费用。即使考虑到不同基本假设下可能的血清型动力学的不确定性，结果也是可靠的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号